Bulletin

Investor Alert

Valneva SE ADR

NAS: VALN

Set Alerts

Market Index

Overview Profile Charts Financials Historical Quotes Analyst Estimates Options SEC Filings Insiders

/marketstate/country/us

Valneva SE ADR

Market closed

VALN

/zigman2/quotes/226552993/composite

11.58

Change

+0.22 +1.94%

Volume

Volume 5,990

Sep 29, 2023, 2:46 p.m.

Quotes are delayed by 20 min

/zigman2/quotes/226552993/composite

Previous close

$ 11.36

$ 11.58

Change

+0.22 +1.94%

Day low

Day high

$11.55

$11.86

Open: 11.86

52 week low

52 week high

$9.07

$17.05

Market cap

$813.77M

Average volume

4,880

P/E ratio

259.64

Rev. per Employee

N/A

EPS

0.04

Dividend

N/A

Div yield

N/A

Ex dividend date

N/A

Compare:

Indexes

Dow(INDU) INDU
Nasdaq (COMP) COMP
S&P 500 (SPX) SPX
Global Dow (GDOW) GDOW

/news/latest/company/us/valn

MarketWatch News on VALN

Pfizer Shuts Trial Sites for Lyme Disease Jab After Standards Breaches

3:44 p.m. Feb. 17, 2023

- Barron's Online
What will insurance coverage of COVID-19 vaccines and treatments look like? The Biden administration is trying to figure that out

10:15 a.m. Aug. 21, 2022

- Jaimy Lee
Pfizer, Valneva begin major test of first possible Lyme vaccine in 20 years

5:19 p.m. Aug. 8, 2022

- Associated Press
Pfizer makes equity investment in Valneva as they prepare for Phase 3 trial of Lyme disease vaccine candidate

7:42 a.m. June 21, 2022

- Jaimy Lee
FDA says Pfizer three-shot vaccine is safe for children under 5, ahead of panel meeting that will also review Moderna’s two-shot regimen

8:13 a.m. June 14, 2022

- Ciara Linnane
Valneva's stock slides after saying Europe may not order the company's COVID-19 vaccine candidate

8:31 a.m. June 13, 2022

- Jaimy Lee
Valneva says the European Medicines Agency accepted application for its COVID-19 vaccine

8:38 a.m. May 19, 2022

- Jaimy Lee
Pfizer, Valneva plan to move Lyme disease vaccine candidate into Phase 3 trial

7:59 a.m. April 26, 2022

- Jaimy Lee
China’s latest COVID outbreak spooks investors, while U.S. cases and hospitalizations are rising again

7:44 a.m. April 26, 2022

- Ciara Linnane
Valneva says the EMA wants additional data about its experimental COVID-19 shot

8:40 a.m. April 25, 2022

- Jaimy Lee
New COVID-19 booster candidates are still being developed as omicron spreads

10:40 a.m. Dec. 17, 2021

- Jaimy Lee
Valneva's stock is up 14% after the company shares promising data for its COVID-19 booster candidate

1:54 p.m. Dec. 16, 2021

- Jaimy Lee
A new study finds that most COVID-19 boosters strengthen immunity, though there is no winning shot

8:08 a.m. Dec. 6, 2021

- Jaimy Lee
Here’s ‘one of the most bullish signals’ ever for bitcoin that many investors may have missed

7:25 a.m. Oct. 18, 2021

- Barbara Kollmeyer
Valneva shares spike after saying vaccine candidate outperformed AstraZeneca’s

7:25 a.m. Oct. 18, 2021

- Steve Goldstein
Coronavirus tally: Global cases of COVID-19 top 240 million and U.S. edges toward 725,000 fatalities

7:04 a.m. Oct. 18, 2021

- Ciara Linnane
Valneva shares jump 30% after saying vaccine candidate outperformed AstraZeneca's

3:47 a.m. Oct. 18, 2021

- Steve Goldstein
Allowing people to mix COVID-19 vaccines could cut into Pfizer and Moderna’s revenue next year

8:07 a.m. Oct. 11, 2021

- Jaimy Lee
Biden to announce new pandemic steps ahead of U.N. meeting Tuesday, as global COVID-19 case tally nears 225 million

7:28 a.m. Sept. 14, 2021

- Ciara Linnane
Booster dose of COVID vaccines to be given to U.K. volunteers in new trial

3:56 p.m. May 21, 2021

- Lina Saigol
Loading more headlines...

/news/nonmarketwatch/company/us/valn

Other News on VALN

Valneva (VALN) Up on Antibody Persistence Data on Chikungunya Jab

9:16 a.m. Dec. 6, 2022

- Zacks.com
Valneva (VALN) Up on 6-Month Lyme Disease Jab Persistence Data

11:54 a.m. Dec. 2, 2022

- Zacks.com
Wall Street Analysts See a 65% Upside in Valneva SE Sponsored ADR (VALN): Can the Stock Really Move This High?

10:55 a.m. Nov. 16, 2022

- Zacks.com
Valneva SE (VALN) Q3 2022 Earnings Call Transcript

4:52 p.m. Nov. 10, 2022

- Seeking Alpha
GENERAL AMERICAN INVESTORS CO INC Buys 2, Sells 3 in 3rd Quarter

5:00 p.m. Oct. 31, 2022

- GuruFocus.com
All You Need to Know About Valneva SE Sponsored ADR (VALN) Rating Upgrade to Buy

12:00 p.m. Oct. 12, 2022

- Zacks.com
Valneva (VALN) Stock Down 66% in the Past 6 Months: Here's Why

12:39 p.m. Sept. 26, 2022

- Zacks.com

/news/pressrelease/company/us/valn

Press Releases on VALN

Valneva Reports First Quarter 2023 Financial Results and Provides Corporate Updates

1:00 a.m. May 4, 2023

- GlobeNewswire
Valneva Announces Filing of 2022 Universal Registration Document and US Form 20-F

1:00 a.m. March 31, 2023

- GlobeNewswire
Valneva to Present on its Chikungunya Vaccine Candidate and Host a Roundtable at the 23rd World Vaccine Congress in Washington D.C.

1:00 a.m. March 30, 2023

- GlobeNewswire
Valneva Reports Full Year 2022 Results and Provides Corporate Updates

2:00 a.m. March 23, 2023

- GlobeNewswire
Valneva Provides Clinical and Regulatory Updates for its COVID-19 Vaccine VLA2001

2:00 a.m. March 2, 2023

- GlobeNewswire
Valneva to Present at the Cowen 43rd Annual Healthcare Conference

12:45 p.m. March 1, 2023

- GlobeNewswire
FDA Accepts Valneva's Chikungunya Vaccine License Application for Priority Review

2:00 a.m. Feb. 20, 2023

- GlobeNewswire
Pfizer and Valneva Issue Update on Phase 3 Clinical Trial Evaluating Lyme Disease Vaccine Candidate VLA15

2:00 a.m. Feb. 17, 2023

- GlobeNewswire
Valneva Reports Full Year 2022 Revenue and Cash, Provides First 2023 Guidance

2:00 a.m. Feb. 16, 2023

- GlobeNewswire
Valneva Completes Enrollment for Adolescent Phase 3 Trial of Single-Shot Chikungunya Vaccine Candidate

2:00 a.m. Feb. 14, 2023

- GlobeNewswire
Valneva Reports Further Heterologous Booster Data for its inactivated COVID-19 vaccine

1:30 p.m. Dec. 30, 2022

- GlobeNewswire
Valneva Completes BLA Submission to U.S. FDA for its Single-Shot Chikungunya Vaccine Candidate

2:00 a.m. Dec. 23, 2022

- GlobeNewswire
Valneva to Conduct Investor Meetings during the J.P. Morgan Healthcare Conference and Oddo BHF Forum

12:45 p.m. Dec. 21, 2022

- GlobeNewswire
Valneva Hosts Investor Day in New York City

2:00 a.m. Dec. 6, 2022

- GlobeNewswire
Valneva Reports Positive 12-Month Antibody Persistence Data for Single-Shot Chikungunya Vaccine Candidate

2:00 a.m. Dec. 5, 2022

- GlobeNewswire
Valneva and Pfizer Report Six-Month Antibody Persistence Data in Children and Adults for Lyme Disease Vaccine Candidate

2:00 a.m. Dec. 1, 2022

- GlobeNewswire
Valneva to Host Investor Day in New York City

1:00 p.m. Nov. 29, 2022

- GlobeNewswire
Valneva Appoints Dipal Patel as Chief Commercial Officer

2:00 a.m. Nov. 17, 2022

- GlobeNewswire
Valneva Reports Nine-Month 2022 Results and Provides Corporate Updates

2:00 a.m. Nov. 10, 2022

- GlobeNewswire
Valneva to Present and Hold Investor Meetings at the Jefferies London Healthcare Conference

12:45 p.m. Nov. 7, 2022

- GlobeNewswire
Loading more headlines...

Rates »

Mortgage Equity Savings Auto

National averages from Bankrate.com

MarketWatch.com

Follow MarketWatch
RSS
Podcasts

Intraday Data provided by FACTSET and subject to terms of use. Historical and current end-of-day data provided by FACTSET. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.

Valneva SE ADR

MarketWatch News on VALN

Other News on VALN

Press Releases on VALN

Rates »

Latest News

dow

nasdaq

s&p 500

Kiosk